Revlimid at Biology Products
Revlimid at Biology Technology
Revlimid at Medicine News
Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
A new drug treatment,
Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.// The exact cause of MDS is not known. However, increased incidence of MDS has been noticed following radiotherapy or chemotherapy. Transfusion of blood...
Revlimid Approved By FDA For Multiple Myeloma
The U.S. Food and Drug Administration has approved the anemia drug
Revlimid (lenalidomide) as a treatment for multiple myeloma, which is a type of blood cancer//. Celgene Corp, which makes this drug will now be able to market
Revlimid for use in multiple myeloma. The treatment regimen demands that the drug be combined with the steroid dexamethasone in patients with multiple myeloma, w...
Revlimid at Medicine Products
Revlimid at Medicine Technology
The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on
REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...
Study Continues to Show Patients With Myelodysplastic Syndromes
Treated With Revlimid are Living Longer and Remaining Transfusion
Independent
Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating
Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...